Get the Daily Brief
Latest Biotech News
CDC cuts routine childhood vaccine recommendations to 11
Federal health officials announced an immediate reduction in the CDC’s routine pediatric vaccine recommendations to 11 diseases, a change implemented under HHS direction and outside the Advisory...
New tools map base‑editor off‑targets and Cas3 yields large TTR deletions
Researchers published two genome‑editing advances: St. Jude Children’s Research Hospital reported CHANGE‑seq‑BE, an unbiased method to map base‑editor off‑target activity and support safety...
Insilico’s Hong Kong IPO... Raises ~$292M, then signs Servier oncology pact
Insilico Medicine completed an oversubscribed Hong Kong IPO and immediately converted that momentum into a multiyear oncology R&D collaboration with Servier. The company priced its listing and...
Singapore’s Deep Intelligent Pharma raises $50M — aims to automate clinical trials
Deep Intelligent Pharma closed a $50 million Series D round to scale its AI-driven clinical trial automation platform. The financing was led by CDH Baifu with participation from existing backers...
Sanofi doubles down on AI biologics—new deals worth up to $2.56B and $160M near term
Sanofi expanded its partnerships with AI-enabled discovery firms, announcing a large biotherapeutics collaboration with Earendil that could reach $2.56 billion and a separate near-term commitment...
Zenas’ Phase III win — and a market shock: trial success meets steep share drop
Zenas Biopharma reported that obexelimab met the Phase III primary endpoint in the Indigo trial for IgG4‑related disease, demonstrating a statistically significant 56% reduction in flare risk...
Wegovy pill rollout: Novo Nordisk ships oral semaglutide and sets tiered pricing
Novo Nordisk began shipping an oral formulation of semaglutide marketed as a Wegovy pill in the U.S., with pharmacies filling prescriptions immediately. The company announced a tiered pricing...
Moderna files for mRNA flu shot approval across major markets
Moderna submitted regulatory applications for its mRNA influenza vaccine, mRNA‑1010, to agencies in the U.S., Europe, Canada and Australia, seeking approval for use in adults aged 50 and older....
CRISPR–Cas3 deletes mutant TTR in vivo — large deletions lower serum TTR ~80%
Researchers evaluated CRISPR–Cas3 as an alternative genome‑editing strategy to induce long deletions at the transthyretin (TTR) locus and achieved near‑complete loss of expression in vitro and...
St. Jude’s CHANGE‑seq‑BE exposes base‑editor off‑targets — supports clinical safety cases
St. Jude researchers unveiled CHANGE‑seq‑BE, a genome‑wide, unbiased method to map off‑target activity induced by base editors. The approach prioritizes sensitivity and resource efficiency to...
Inhalable bispecific exosomes activate T cells — preclinical reversal of ICI resistance
An engineered inhalable exosome platform delivered a bispecific T‑cell activator to pembrolizumab‑resistant metastatic melanoma models and restored antitumor T‑cell activity. The work demonstrates...
CRISPR knockout screens map neuronal differentiation — PEDS1 linked to new disorder
A genome‑wide CRISPR knockout screen identified 331 genes essential for converting embryonic stem cells into neurons and implicated PEDS1 in a previously undescribed neurodevelopmental disorder....
Sanofi buys Dynavax for $2.2bn – bolsters adult immunization
Sanofi agreed to acquire Dynavax Technologies for about $2.2 billion in cash, adding the marketed hepatitis B vaccine HEPLISAV‑B and a phase I/II shingles candidate to its adult immunization...
Moderna seeks mRNA flu approvals: files dossiers across major markets
Moderna has submitted regulatory applications for mRNA‑1010, its seasonal influenza vaccine built on mRNA technology, to regulators in the U.S., Europe, Canada and Australia. The company reported...
Wegovy pill hits U.S. pharmacies: pricing and access move to center stage
Novo Nordisk has begun shipping the oral form of semaglutide branded as Wegovy to U.S. pharmacies, prompting immediate questions about pricing and access. The company said prescriptions could be...
Zenas' phase‑3 win sparks selloff – markets punish cross‑trial comparisons
Zenas Biopharma reported that obexelimab met the primary endpoint in the phase 3 Indigo trial for immunoglobulin G4‑related disease (IgG4‑RD), reducing flare risk by 56% versus placebo over 52...
Singapore’s Deep Intelligent Pharma raises $50M – aims to automate clinical trials
Deep Intelligent Pharma (DIP) closed a $50 million Series D round led by CDH Baifu to expand its autonomous clinical trial automation platform and global commercialization network. The company...
Insilico inks $888M pact with Servier – AI fuels oncology drug discovery
Insilico Medicine signed a multiyear R&D collaboration with Servier valued at up to $888 million to apply Insilico’s AI discovery platform to oncology targets. The agreement includes up‑front and...
Sanofi doubles down on Earendil: second AI biologics pact could top $2.5bn
Sanofi expanded its collaboration with AI‑driven biologics developer Earendil Labs with a follow‑on agreement worth up to $160 million in near‑term checks, supplementing an earlier potential $2.56...
CRISPR–Cas3 deletes TTR in vivo – long‑range edits cut serum TTR dramatically
Researchers reported use of CRISPR–Cas3, a mechanistically distinct genome‑editing system that produces long‑range deletions, to target the transthyretin (TTR) locus in mice. Delivered via lipid...